Zevra Therapeutics (STU:1GDA) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1GDA Zevra Therapeutics Inc STU:1GDA
69 GF Score
Price €9.80
GF Value €17.92
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Zevra Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Zevra Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

STU:1GDA vs TECX, RLMD, ALT: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Zevra Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zevra Therapeutics Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.


STU:1GDA
69GF Score
Zevra Therapeutics Inc STU:1GDA
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zevra Therapeutics (STU:1GDA) Overvalued in 2026?

Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued. The current stock price of €9.80 is trading 45.3% below its estimated GF Value™ of €17.92. GuruFocus considers Zevra Therapeutics to be Possible Value Trap.

Key valuation signals for STU:1GDA:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €17.92 vs. price of €9.80 (45.3% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the STU:1GDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zevra Therapeutics Business Description

Other Exchanges ZVRA:USA
Address 101 Federal Street, Boston, MA, USA, 02110
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score

Get the complete analysis for STU:1GDA

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.80
Price
€17.92
GF Value